It is interesting to note that despite a more severe asthma cohort than that recruited to the phase 3 NAVIGATOR study (with higher baseline exacerbation rates, higher dependence on maintenance OCS and a large proportion of patients who had failed eosinophil‐directed therapy with an anti‐IL5/5R biologic), the clinical remission rate of 35.6% we observed was higher than the 28.5% reported in the NAVIGATOR subjects [12]. The gene discussed is IL5; the disease is asthma.